Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Drug

MicuRx Pharmaceuticals’ MRX-8 Achieves Positive Results in Phase I Clinical Study

Fineline Cube Jun 5, 2024

MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has announced the successful completion...

Company Deals

Zhaoke Ophthalmology Partners with China’s Eye Valley to Establish Ophthalmic Research Institute

Fineline Cube Jun 5, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, has announced that its subsidiary,...

Company Deals

Eli Lilly Acquires QurAlis’ UNC13A-Targeting Compounds for Neurodegenerative Diseases

Fineline Cube Jun 5, 2024

Eli Lilly and Company (NYSE: LLY) has announced the acquisition of global development and commercialization...

Company Drug

Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Recommended for Approval by EMA’s CHMP

Fineline Cube Jun 4, 2024

Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company based in Guangzhou, has received notification that the...

Company Medical Device

Zylox-Tonbridge Medical Technology Earns NMPA Approval for First Vascular Stapler in China

Fineline Cube Jun 4, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices...

Company Deals Drug

Akeso Expands Licensing Deal with Summit Therapeutics for Ivonescimab Bispecific Antibody

Fineline Cube Jun 4, 2024

Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced a supplementary licensing...

Company Drug

Jiangsu Aidea Pharmaceutical Gets Green Light from NMPA for AINUOVirine APIs

Fineline Cube Jun 4, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a biopharmaceutical company based in China, has announced...

Company

China Meheco Group Appoints Yang Guang as Chairman and Legal Representative

Fineline Cube Jun 4, 2024

China Meheco Group Co., Ltd (SHA: 600056) has announced the appointment of Yang Guang to...

Company Drug

Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China

Fineline Cube Jun 4, 2024

Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval...

Company Drug

Legend Biotech’s Carvykti Shows Durable Responses in Multiple Myeloma Patients Post ASCT

Fineline Cube Jun 4, 2024

Legend Biotech Corporation (NASDAQ: LEGN) has announced results from the Phase II CARTITUDE-2 Cohort D...

Company Medical Device

Varian Medical Gets China Approval for Fourth-Generation Halcyon Radiotherapy System

Fineline Cube Jun 4, 2024

Varian Medical Systems (NYSE: VAR), a US-based leader in cancer treatment technology, has announced that...

Company Drug

CSPC Pharmaceutical Secures NMPA Nod for Generic Version of AstraZeneca’s Lynparza

Fineline Cube Jun 4, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Akeso Biopharma’s Ivonescimab Outshines Keytruda in NSCLC Trial, Raises FDA Concerns

Fineline Cube Jun 4, 2024

FiercePharma.com has reported on the reactions of multinational corporation executives to the recent news that...

Company Drug

Gilead and Arcus Biosciences Report Positive Interim Phase II Data for Domvanalimab Combo in GI Cancers

Fineline Cube Jun 4, 2024

Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced interim Phase II data for...

Company Deals

Changchun GeneScience to Distribute TWi Pharma’s Megestrol in China and Southeast Asia

Fineline Cube Jun 4, 2024

Changchun GeneScience Pharmaceutical Co., Ltd, a biopharmaceutical company based in China, has entered into an...

Policy / Regulatory

China’s NHSA and MoF Plan Expansion of Long-term Care Insurance System Pilot Program

Fineline Cube Jun 4, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly issued...

Company Drug

Eli Lilly’s KRAS Inhibitor Olomorasib Shows Promise in Phase I/II Trial for Advanced Solid Tumors

Fineline Cube Jun 4, 2024

Eli Lilly and Company (NYSE: LLY) has presented an update on a Phase I/II clinical...

Policy / Regulatory

Shenzhen’s Draft Proposal for VBP Drug Procurement and Medical Insurance Fund Management Released

Fineline Cube Jun 4, 2024

The Healthcare Security Administration (HSA) Bureau of the Shenzhen municipality has released a “Shenzhen Drug...

Company Drug

Bristol Myers Squibb’s Krazati Meets Primary Endpoint in Late-Stage Lung Cancer Study

Fineline Cube Jun 4, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has announced that a late-stage study for its KRAS...

Company Medical Device

Hygea Medical’s Subsidiary Gets Green Light for Innovative Intrahepatic Puncture Instrument in China

Fineline Cube Jun 3, 2024

Hygea Medical Technology Co., Ltd, a China-based medical device company, has announced that its subsidiary,...

Posts pagination

1 … 380 381 382 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.